Johnson & Johnson news
The WiseView Research desk's stories that name Johnson & Johnson, the latest headlines about it, and the trades members of Congress and company insiders have disclosed. The JNJ page →
- Headline2 Safe S&P 500 Dividend Stocks Boomers Can Buy and Hold Forever
- HeadlineT-Bills Yield Up to 4.45%. Why Would Retirees Choose Dividend Stocks?
- HeadlineJohnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer
- HeadlineNANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma
- HeadlineJohnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial
- HeadlineJ&J Stock Reclaims 50-Day SMA: Is it Time to Buy, Sell or Hold?
- HeadlineUK approves J&J's oral psoriasis pill
- HeadlineProcter & Gamble Jumps 6% as Earnings Beat Draws Defensive Buyers; Johnson & Johnson Rises 3%, Coca-Cola Ticks Up
- HeadlineJNJ Stock Has a New Growth Story, but One Business Needs to Catch Up
- HeadlineSocial Security Isn't Enough: 5 Secure Dividend Stocks to Fund Your Retirement
- HeadlineJohnson & Johnson Reports First Real-World VARIPULSE Pro Platform Data and 12-Month OMNYPULSE Platform Outcomes for Atrial Fibrillation Treatment at APHRS 2026
- HeadlineJohnson & Johnson Raised Its Dividend Every Year. Why Did It Trail the S&P 500?
- Headline3 of the Best Value Stocks to Own
- HeadlineIs Most-Watched Stock Johnson & Johnson (JNJ) Worth Betting on Now?
- HeadlineJohnson & Johnson's Profit Fell 96% Year-Over-Year. But the Dividend Has Risen for 64 Years in a Row
- HeadlineHealthcare ETFs to Buy as JNJ Slips 6% Despite Q3 Earnings Beat
- HeadlineJohnson & Johnson Launches Next-Generation Shockwave™ C2 Aero Fly Coronary IVL Catheter, Cutting IVL Treatment Time in Half
- HeadlineJohnson & Johnson to Showcase the Future of Surgical Intelligence at Abu Dhabi Future Health Summit 2026
- Congress trade disclosuresCongress Trade Disclosures: Doggett, Rulli and Allen Filings, Oct 7
New filings disclose 10 congressional stock trades across three members, with a 30-day median gap between trade and disclosure.
- Headline3 Dividend Kings to Buy Now for Protection Against Rising Rates
- HeadlineJohnson & Johnson announces new data showing TREMFYA® (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistula
- HeadlineJohnson & Johnson Stock Could Be a Defensive Play for the Years Ahead
- HeadlineJNJ Investors with $100,000 in Losses Have Opportunity to Join Johnson & Johnson Fraud Investigation with SBS Law
- HeadlineJohnson & Johnson Just Raised Its Sales Outlook Again. Here's Why the Dividend King Is Still a Buy.
- HeadlineJohnson & Johnson: 3 Key Takeaways for Long-Term Investors
- HeadlineJNJ Q3 Earnings Call Highlights Growth Outlook and MedTech Challenges
- HeadlineJ&J Beat and Raised. The Stock Fell Anyway.
- HeadlineJohnson & Johnson shares SLIDE nearly 6% despite stronger full-year forecast
- HeadlineJohnson & Johnson: Keep Calm And Hold On
- HeadlineJohnson & Johnson (JNJ) Q3 2026 Earnings Call Transcript
- HeadlineJohnson & Johnson shares fall following earnings
- HeadlineQUICK SPARK: J&J Eyes Worst Day Since April 2025 with MedTech Miss
- HeadlineJohnson & Johnson Q3 Earnings: Talc Resolution Offer Impacts Earnings, MedTech Slows Growth
- HeadlineSurgical Precision, Sustainable Returns: Johnson & Johnson Secures its Cash Flow Runway
- HeadlineWhat Johnson & Johnson (JNJ) Said on Its Q3 Earnings Call
- HeadlineJ&J Q3 Earnings Beat Estimates, Sales Miss, View Raised, Stock Down
- HeadlineJohnson & Johnson raises 2026 guidance as quarterly sales climb
- HeadlineCompared to Estimates, Johnson & Johnson (JNJ) Q3 Earnings: A Look at Key Metrics
- HeadlineWall Street Analysts See Johnson & Johnson (JNJ) as a Buy: Should You Invest?
- HeadlineJohnson & Johnson (JNJ) Q3 Earnings Surpass Estimates
- Headline4 Dividend Kings Retirees Can Buy and Hold Forever: Safe Income for the Next 60 Years
- HeadlineJohnson & Johnson Hikes Earnings Guidance but Pharma Growth Masks a MedTech Stumble
- HeadlineJ&J Is Leaning Toward Spinning Out Its Hips-And-Knees Business
- HeadlineJohnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026
- HeadlineJohnson & Johnson reports Q3 2026 results, raises 2026 guidance
- HeadlineNew TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups
- HeadlineTREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease
- HeadlineTreasury Bills vs Dividend Stocks: Which Income Stream Actually Fits Your Retirement
- HeadlineHere's How Much Johnson & Johnson Stock Is Expected to Move After Earnings
- CongressRo Khanna bought $15,001 - $50,000 of JNJ
- CongressRo Khanna bought $1,001 - $15,000 of JNJ
- HeadlineJ&J Stock Ahead of Q3 Earnings: Should You Buy, Sell or Hold?
- Headline4 Dividend Stocks Boomers Can Safely Buy Now and Hold Forever
- CongressLloyd Doggett bought $1,001 - $15,000 of JNJ
- CongressThomas Kean sold $1,001 - $15,000 of JNJ
- CongressJohn Boozman sold $1,001 - $15,000 of JNJ
- CongressRo Khanna sold $1,001 - $15,000 of JNJ
- CongressRo Khanna bought $1,001 - $15,000 of JNJ
- CongressTommy Tuberville sold $15,001 - $50,000 of JNJ
Headlines link to their publishers. Members of Congress disclose ranges, not exact amounts, and may file weeks after the trade; insider filings are open-market purchases and sales from SEC Form 4. For information only, not investment advice.